Gbert, Your solution to the problem is simple and rational. For that reason I don't think the court will see it that way. The hatch Waxman bill created a flawed system. The supreme court will need to sort this out eventually. I think the GSK v Teva decision might represent a change in the thinking of the court. Patent law should not be violated in order to give unfair advantage to generic companies. Our R-IT patents are solid. The generic companies are infringing. We need to see how Hikma responds to the suite. Just my opinion. Sleven,
Who would monitor and enforce this production? Not to mention that these finished product sellers like Hikma, etc don’t manufacture V. They just buy from 3rd party manufacturers.
Market Data 
Markets 
AI
